3α-Aminocholestane

Name: 3α-Aminocholestane
Brand: MedChemExpress
SKU: HY-19776
Rating: 5.0 (4 reviews)

Cat. No.: HY-19776 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

3α-Aminocholestane is a selective SH2 domain-containing inositol-5′-phosphatase 1 (SHIP1) inhibitor with an IC₅₀ of ~2.5 μM.

For research use only. We do not sell to patients.

3α-Aminocholestane Chemical Structure

CAS No. : 2206-20-4

Size	Price	Stock	Quantity
Solution
10 mM * 1 mL in Ethanol	USD 85	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 100	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 140	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 290	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 460	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 790	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

4 Publications Citing Use of MCE 3α-Aminocholestane

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

3α-Aminocholestane is a selective SH2 domain-containing inositol-5′-phosphatase 1 (SHIP1) inhibitor with an IC₅₀ of ~2.5 μM.

IC₅₀ & Target

IC50: 2.5 μM (SHIP1)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
MDCK-II	IC₅₀	1.9 μM Compound: 1b	Antiviral activity against Influenza A/PR8/34 (H1N1) virus infected in MDCK2 cells assessed as inhibition of virus reproduction by ELISA Antiviral activity against Influenza A/PR8/34 (H1N1) virus infected in MDCK2 cells assessed as inhibition of virus reproduction by ELISA	[PMID: 23916260]

In Vitro

OPM2 cell viability is effectively reduced by 3α-Aminocholestane (3AC) treatment. RPMI8226 and U266 cells show significantly less sensitivity to 3α-Aminocholestane treatment when compare with OPM2 cells, although viability is decreased significantly at concentrations of ≥12.5 μM. Treatment with 3α-Aminocholestane for 36 h severely reduces the percentage of cells in the S phase, which is accompanied by an increase of cells in the G2/M phase. In contrast, in the less proliferative RPMI8226 and U266 cells, cell cycle progression is blocked in the G0/G1 phase upon 3α-Aminocholestane treatment, in conjunction with a reduced percentage of cells undergoing the S phase^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

It is found that 3α-Aminocholestane (3AC) results in reduced multiple myeloma (MM) growth in vivo, as determined by quantitation of free human Igλ light chain in the plasma after OPM2 challenge. In addition, reduced numbers of circulating OPM2 cells, as determined by human HLA-ABC staining, is observed in peripheral blood from 3α-Aminocholestane-treated mice compare with vehicle controls. Most importantly, 3α-Aminocholestane treatment results in significantly enhanced survival of mice after tumor challenge. In 3α-Aminocholestane-treated mice that resist treatment, it is found that MM tumors exhibit an upregulation of SHIP2, reminiscent of in vitro treatment of OPM2 cells and suggesting that SHIP1 inhibition may select for tumor cells with increased SHIP2 expression^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

387.68

Formula

C₂₇H₄₉N

CAS No.

2206-20-4

Appearance

Solid

Color

White to off-white

SMILES

CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](N)CC[C@]4(C)[C@@]3([H])CC[C@@]21C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

Ethanol : 50 mg/mL (128.97 mM; Need ultrasonic)

DMSO : 1 mg/mL (2.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5794 mL	12.8972 mL	25.7945 mL
5 mM	0.5159 mL	2.5794 mL	5.1589 mL
10 mM	0.2579 mL	1.2897 mL	2.5794 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.25 mg/mL (8.38 mM); Clear solution

This protocol yields a clear solution of ≥ 3.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (32.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 3.25 mg/mL (8.38 mM); Clear solution

This protocol yields a clear solution of ≥ 3.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (32.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (278 KB) SDS (252 KB)

COA (247 KB) HNMR (258 KB)

Handling Instructions (2659 KB)

References

[1]. Chen Z, et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2015 May 21;521(7552):357-61.

[2]. Gwenny M Fuhler, et al. Therapeutic Potential of SH2 Domain-Containing Inositol-5′-Phosphatase 1 (SHIP1) and SHIP2 Inhibition in Cancer. Mol Med. 2012 Feb 10;18:65-75. [Content Brief]

Cell Assay ^[2]	Cells are treated in triplicate or more with increasing concentrations of compounds (including 3α-Aminocholestane). Cell viability is determined with a Cell Counting Kit according to the manufacturer’s instructions. The odds density (OD) of compound (including 3α-Aminocholestane )-treated cells is divided by the OD of their vehicle control, and the viability is expressed as a percentage of untreated cells. Results are expressed as mean±standard error of the mean (SEM) of three individual experiments. For phosphatidyl inositol phosphates (PIP) add-back experiments, MCF-7 cells are treated for 2 h with 10 μM SHIP inhibitors (including 3α-Aminocholestane ), after which cells are washed and fresh medium is added. Cells are subsequently cultured in the absence (0 μM) or presence (10 or 20 μM) of either PtdIns(3,4)P₂-diC16 (P-3416) or PtdIns(3,5)P₂-diC16 (P-3516) for 36 h, after which cell viability is determined by the Cell Counting Kit^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	NOD/SCID/γcIL2R (NSG) mice are injected intraperitoneally with 1×10⁷ OPM2 cells and 6 h later receive an initial injection of 3α-Aminocholestane (3AC) or vehicle. 3α-Aminocholestane is suspended in a 0.3% Klucel/H₂O solution at 11.46 mM and administered by intraperitoneal injection of 100 μL solution. Vehicle-treated mice receive 100 μL injection of 0.3% Klucel/H₂O solution. The mice are then treated with 3α-Aminocholestane or vehicle daily for the next 6 d and then twice per week in the remaining 15 wks of the survival study^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Chen Z, et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2015 May 21;521(7552):357-61. [2]. Gwenny M Fuhler, et al. Therapeutic Potential of SH2 Domain-Containing Inositol-5′-Phosphatase 1 (SHIP1) and SHIP2 Inhibition in Cancer. Mol Med. 2012 Feb 10;18:65-75. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / Ethanol	1 mM	2.5794 mL	12.8972 mL	25.7945 mL	64.4862 mL
Ethanol	5 mM	0.5159 mL	2.5794 mL	5.1589 mL	12.8972 mL
	10 mM	0.2579 mL	1.2897 mL	2.5794 mL	6.4486 mL
	15 mM	0.1720 mL	0.8598 mL	1.7196 mL	4.2991 mL
	20 mM	0.1290 mL	0.6449 mL	1.2897 mL	3.2243 mL
	25 mM	0.1032 mL	0.5159 mL	1.0318 mL	2.5794 mL
	30 mM	0.0860 mL	0.4299 mL	0.8598 mL	2.1495 mL
	40 mM	0.0645 mL	0.3224 mL	0.6449 mL	1.6122 mL
	50 mM	0.0516 mL	0.2579 mL	0.5159 mL	1.2897 mL
	60 mM	0.0430 mL	0.2150 mL	0.4299 mL	1.0748 mL
	80 mM	0.0322 mL	0.1612 mL	0.3224 mL	0.8061 mL
	100 mM	0.0258 mL	0.1290 mL	0.2579 mL	0.6449 mL